Eastern Mediterranean (WHO region) vs Saudi Arabia: Pneumococcal conjugate second or third-dose vaccines (PCVc)

Eastern Mediterranean (WHO region)
61.0%
in 2025
Saudi Arabia
98.0%
in 2025
Eastern Mediterranean (WHO region) rank
9th
Saudi Arabia rank
11th

Pneumococcal conjugate second or third-dose vaccines (PCVc) over time

  • Eastern Mediterranean (WHO region)
  • Saudi Arabia
020406080100200820162025

How they compare

Saudi Arabia currently reports 98.0% against 61.0% in Eastern Mediterranean (WHO region), a difference of 37.0%.

That makes Saudi Arabia's figure about 1.6 times Eastern Mediterranean (WHO region)'s.

Across all 18 years both countries report, Saudi Arabia has been ahead every year.

Eastern Mediterranean (WHO region) ranks 9th and Saudi Arabia ranks 11th of 11 groups.

Saudi Arabia has averaged higher in every one of the 3 decades both report.

Head to head by decade

Decade Eastern Mediterranean (WHO region) Saudi Arabia Difference Ahead
2000s 2.0% 49.0% 47.0% Saudi Arabia
2010s 37.1% 97.8% 60.7% Saudi Arabia
2020s 54.7% 96.8% 42.2% Saudi Arabia

Averages of every year both report within each decade.

Frequently asked questions

Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Eastern Mediterranean (WHO region) or Saudi Arabia?
Saudi Arabia, at 98.0% against 61.0% in Eastern Mediterranean (WHO region) as of 2025.
What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Eastern Mediterranean (WHO region) and Saudi Arabia?
37.0%, with Saudi Arabia ahead.
How many years of comparable data are there for Eastern Mediterranean (WHO region) and Saudi Arabia?
18 years are reported by both, from 2008 to 2025.
How do Eastern Mediterranean (WHO region) and Saudi Arabia rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
Eastern Mediterranean (WHO region) ranks 9th and Saudi Arabia ranks 11th of 11 groups.
Where does this data come from?
World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

Share, cite or embed this page

Cite this page

Eastern Mediterranean (WHO region) vs Saudi Arabia: Pneumococcal conjugate second or third-dose vaccines (PCVc). Statizoid, drawing on World Health Organization, Global Health Observatory. Retrieved 01 September 2026, from https://health.statizoid.com/compare/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/eastern-mediterranean-who-region/saudi-arabia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY-NC-SA 3.0 IGO (WHO); please keep the attribution.

<a href="https://health.statizoid.com/compare/pneumococcal-conjugate-second-or-third-dose-vaccines-pcvc-immunization-coverage-by-the/eastern-mediterranean-who-region/saudi-arabia/">Eastern Mediterranean (WHO region) vs Saudi Arabia: Pneumococcal conjugate second or third-dose vaccines (PCVc)</a> — Statizoid

About this data

Indicator
Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC)
Source
World Health Organization, Global Health Observatory
Licence
CC BY-NC-SA 3.0 IGO (WHO)
Coverage
206 places, 3,705 data points, 2008–2025
Last refreshed